About Aimmune Therapeutics (NASDAQ:AIMT)
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. The company has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AIMT
CUSIPN/A
Phone650-614-5220
Debt
Debt-to-Equity RatioN/A
Current Ratio7.11%
Quick Ratio7.11%
Price-To-Earnings
Trailing P/E Ratio-12.14
Forward P/E Ratio-11.39
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.50 per share
Price / Book8.85
Profitability
EPS (Most Recent Fiscal Year)($2.61)
Net Income$-131,320,000.00
Net MarginsN/A
Return on Equity-59.03%
Return on Assets-53.97%
Miscellaneous
Employees131
Outstanding Shares58,020,000
Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions
What is Aimmune Therapeutics' stock symbol?
Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."
How were Aimmune Therapeutics' earnings last quarter?
Aimmune Therapeutics (NASDAQ:AIMT) announced its quarterly earnings results on Monday, March, 12th. The biotechnology company reported ($0.81) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.72) by $0.09. View Aimmune Therapeutics' Earnings History.
What price target have analysts set for AIMT?
8 brokers have issued 12 month target prices for Aimmune Therapeutics' stock. Their predictions range from $30.00 to $80.00. On average, they anticipate Aimmune Therapeutics' share price to reach $60.1250 in the next twelve months. View Analyst Ratings for Aimmune Therapeutics.
What are Wall Street analysts saying about Aimmune Therapeutics stock?
Here are some recent quotes from research analysts about Aimmune Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "Quick thoughts on today’s market reaction. Absent hearing pointed criticism of the PALISADE data, the market’s reaction befuddles us somewhat. We suppose AIMT owners could be taking profits, the stock is +50% since October 20, 2017, as compared with +1% for the NBI. Would-be investors might be disinclined to buy the stock on release of positive top-line results that were anticipated (in one fashion of another) and might desire a view of additional data. We are mindful, too, that the commercial launch of the product is likely 15-18 months hence." (2/20/2018)
- 2. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (1/31/2018)
Who are some of Aimmune Therapeutics' key competitors?
Some companies that are related to Aimmune Therapeutics include Alkermes (ALKS), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Galápagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN) and GW Pharmaceuticals (GWPH).
Who are Aimmune Therapeutics' key executives?
Aimmune Therapeutics' management team includes the folowing people:
- Dr. Stephen George Dilly, Pres, CEO & Director (Age 58)
- Mr. Jeffrey H. Knapp, Chief Operating Officer (Age 52)
- Dr. Daniel C. Adelman M.D., Chief Medical Officer (Age 61)
- Mr. Eric H. Bjerkholt, CFO & Principal Accounting Officer (Age 58)
- Dr. Laura Hansen Ph.D., VP of Investor Relations
When did Aimmune Therapeutics IPO?
(AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.
Has Aimmune Therapeutics been receiving favorable news coverage?
Media stories about AIMT stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aimmune Therapeutics earned a news impact score of 0.08 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.53 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Aimmune Therapeutics' major shareholders?
Aimmune Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include
FMR LLC
(5.05%) and
FMR LLC
(5.05%). Company insiders that own Aimmune Therapeutics stock include Bakker Juliet Tammenoms, Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Foresite Capital Fund Ii, LP, Kathryn E Falberg, Mary M Rozenman, Patrick G Enright, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Institutional Ownership Trends for Aimmune Therapeutics.
How do I buy shares of Aimmune Therapeutics?
Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aimmune Therapeutics' stock price today?
One share of AIMT stock can currently be purchased for approximately $30.98.
How big of a company is Aimmune Therapeutics?
Aimmune Therapeutics has a market capitalization of $1.85 billion. The biotechnology company earns $-131,320,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. Aimmune Therapeutics employs 131 workers across the globe.
How can I contact Aimmune Therapeutics?
Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected]
MarketBeat Community Rating for Aimmune Therapeutics (AIMT)
MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aimmune Therapeutics (NASDAQ:AIMT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Aimmune Therapeutics in the last 12 months. Their average twelve-month price target is $60.1250, suggesting that the stock has a possible upside of 94.08%. The high price target for AIMT is $80.00 and the low price target for AIMT is $30.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $60.1250 | $60.1250 | $59.00 | $51.00 |
| Price Target Upside: | 94.08% upside | 67.15% upside | 51.28% upside | 98.75% upside |
Aimmune Therapeutics (NASDAQ:AIMT) Consensus Price Target History
Aimmune Therapeutics (NASDAQ:AIMT) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Aimmune Therapeutics (NASDAQ:AIMT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aimmune Therapeutics (NASDAQ AIMT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.70%
Institutional Ownership Percentage: 64.35%
Aimmune Therapeutics (NASDAQ AIMT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/5/2018 | Douglas T Sheehy | Insider | Sell | 3,523 | $36.52 | $128,659.96 | 32,500 |  |
| 3/1/2018 | Mary M Rozenman | Insider | Sell | 1,807 | $33.10 | $59,811.70 | | |
| 2/26/2018 | Eric Bjerkholt | CFO | Buy | 3,125 | $32.00 | $100,000.00 | | |
| 2/26/2018 | Kathryn E Falberg | Director | Buy | 30,000 | $32.00 | $960,000.00 | | |
| 2/22/2018 | Bakker Juliet Tammenoms | Major Shareholder | Buy | 9,375 | $32.00 | $300,000.00 | 16,651 | |
| 2/22/2018 | Patrick G Enright | Director | Buy | 15,593 | $32.00 | $498,976.00 | 22,869 | |
| 2/5/2018 | Douglas T Sheehy | Insider | Sell | 1,648 | $35.87 | $59,113.76 | | |
| 2/1/2018 | Mary M Rozenman | Insider | Sell | 6,592 | $35.36 | $233,093.12 | | |
| 1/24/2018 | Douglas T Sheehy | Insider | Sell | 1,875 | $38.15 | $71,531.25 | 1,875 | |
| 1/16/2018 | Daniel C Md Adelman | Insider | Sell | 9,933 | $40.00 | $397,320.00 | 26,784 | |
| 1/12/2018 | Daniel C Md Adelman | Insider | Sell | 26,784 | $40.00 | $1,071,360.00 | 26,784 | |
| 1/4/2018 | Douglas T Sheehy | Insider | Sell | 1,648 | $37.33 | $61,519.84 | 1,648 | |
| 1/2/2018 | Susan E Barrowcliffe | Insider | Sell | 75,000 | $37.14 | $2,785,500.00 | | |
| 12/27/2017 | Daniel C Md Adelman | Insider | Sell | 3,283 | $40.00 | $131,320.00 | 3,283 | |
| 12/26/2017 | Douglas T Sheehy | Insider | Sell | 1,875 | $39.44 | $73,950.00 | 1,875 | |
| 12/4/2017 | Douglas T Sheehy | Insider | Sell | 1,906 | $38.66 | $73,685.96 | 1,906 | |
| 11/30/2017 | Douglas T Sheehy | Insider | Sell | 3,750 | $37.00 | $138,750.00 | 3,750 | |
| 11/9/2017 | Douglas T Sheehy | Insider | Sell | 1,905 | $33.00 | $62,865.00 | 1,905 | |
| 10/23/2017 | Douglas T Sheehy | Insider | Sell | 47,425 | $34.44 | $1,633,317.00 | 34,300 | |
| 10/16/2017 | Stephen George Dilly | CEO | Sell | 1,154 | $26.24 | $30,280.96 | | |
| 10/6/2017 | Stephen George Dilly | CEO | Sell | 4,047 | $26.31 | $106,476.57 | | |
| 10/5/2017 | Stephen George Dilly | CEO | Sell | 14,689 | $26.24 | $385,439.36 | | |
| 10/4/2017 | Stephen George Dilly | CEO | Sell | 80,110 | $26.23 | $2,101,285.30 | | |
| 9/25/2017 | Stephen George Dilly | CEO | Sell | 100,000 | $25.01 | $2,501,000.00 | | |
| 9/25/2017 | Susan E Barrowcliffe | Insider | Sell | 20,000 | $25.00 | $500,000.00 | 20,000 | |
| 9/7/2017 | Mary M Rozenman | Insider | Sell | 30,000 | $22.50 | $675,000.00 | 30,129 | |
| 9/6/2017 | Susan E Barrowcliffe | Insider | Sell | 18,390 | $22.00 | $404,580.00 | 3,223 | |
| 7/27/2017 | Susan E Barrowcliffe | Insider | Sell | 500 | $22.00 | $11,000.00 | 500 | |
| 7/26/2017 | Stephen George Dilly | Insider | Sell | 50,000 | $21.46 | $1,073,000.00 | | |
| 7/25/2017 | Susan E Barrowcliffe | Insider | Sell | 6,110 | $22.00 | $134,420.00 | 960 | |
| 7/21/2017 | Douglas T. Sheehy | Insider | Sell | 7,460 | $21.66 | $161,583.60 | | |
| 7/17/2017 | Mary M Rozenman | Insider | Sell | 14,940 | $21.44 | $320,313.60 | 9,103 | |
| 7/5/2017 | Mary M Rozenman | Insider | Sell | 45,060 | $20.85 | $939,501.00 | 30,129 | |
| 7/3/2017 | Susan E Barrowcliffe | Insider | Sell | 15,000 | $20.26 | $303,900.00 | 15,000 | |
| 6/23/2017 | Stephen George Dilly | Insider | Sell | 49,400 | $20.21 | $998,374.00 | | |
| 5/12/2017 | Eric Bjerkholt | CFO | Buy | 5,000 | $19.84 | $99,200.00 | 5,000 | |
| 5/10/2017 | Stephen George Dilly | Insider | Sell | 600 | $20.15 | $12,090.00 | | |
| 4/3/2017 | Warren L Desouza | CFO | Sell | 15,000 | $21.58 | $323,700.00 | 35,681 | |
| 3/21/2017 | Warren L Desouza | CFO | Sell | 10,000 | $22.95 | $229,500.00 | 30,681 | |
| 11/4/2016 | Mary M Rozenman | Insider | Sell | 24,096 | $17.60 | $424,089.60 | 24,096 | |
| 10/5/2016 | Mary M Rozenman | Insider | Sell | 25,000 | $16.80 | $420,000.00 | 25,000 | |
| 9/8/2016 | Mary M Rozenman | Insider | Sell | 30,000 | $16.80 | $504,000.00 | 30,000 | |
| 5/31/2016 | Foresite Capital Fund Ii, L.P. | Major Shareholder | Sell | 240,000 | $15.23 | $3,655,200.00 | | |
| 3/29/2016 | Longitude Capital Partners Ii, | Major Shareholder | Buy | 78,504 | $13.87 | $1,088,850.48 | | |
(Data available from 1/1/2013 forward)
Aimmune Therapeutics (NASDAQ AIMT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Backing Blackstone For A Decade - Cramer's Lightning Round (4/23/18)
seekingalpha.com - April 24 at 8:30 AM |
 | Global Peanut Allergy Therapeutics - 2018 Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations ...
www.businesswire.com - April 21 at 8:31 AM |
 | Market Trends Toward New Normal in Genuine Parts, Energizer, Arthur J ...
globenewswire.com - April 20 at 5:11 PM |
 | Market Trends Toward New Normal in Genuine Parts, Energizer, Arthur J. Gallagher, Aimmune Therapeutics, Roku, and Premier — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - April 19 at 8:30 AM |
 | Aimmune Therapeutics (AIMT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 16 at 1:44 AM |
| Brokerages Expect Aimmune Therapeutics (AIMT) Will Announce Earnings of -$0.66 Per Share
www.americanbankingnews.com - April 10 at 9:13 PM |
| Aimmune Therapeutics (AIMT) Given Outperform Rating at Wedbush
www.americanbankingnews.com - April 6 at 11:11 AM |
| Aimmune Therapeutics (AIMT) PT Set at $62.00 by Piper Jaffray
www.americanbankingnews.com - April 5 at 12:03 PM |
| Aimmune Therapeutics (AIMT) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 8:10 PM |
| Is This Why AnaptysBio Inc. Fell on Monday?
finance.yahoo.com - April 3 at 8:39 AM |
| Aimmune Therapeutics (AIMT) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - March 30 at 6:16 PM |
| Credit Suisse Group Analysts Give Aimmune Therapeutics (AIMT) a $45.00 Price Target
www.americanbankingnews.com - March 28 at 7:04 PM |
| Protecting children from severe peanut allergies
finance.yahoo.com - March 27 at 5:03 PM |
| U.S. Biotech/Pharma Sector Daily Observations Letter: March 26, 2018
seekingalpha.com - March 27 at 8:44 AM |
| After-hours buzz: RHT, ANAB & more
finance.yahoo.com - March 27 at 8:44 AM |
| Aimmune Therapeutics (AIMT) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - March 26 at 3:13 PM |
| Aimmune Therapeutics (AIMT) Now Covered by Royal Bank of Canada
www.americanbankingnews.com - March 25 at 8:16 AM |
| Credit Suisse Group Reiterates "$45.00" Price Target for Aimmune Therapeutics (AIMT)
www.americanbankingnews.com - March 24 at 8:55 PM |
| Aimmune Therapeutics Inc (AIMT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 22 at 1:36 AM |
| Wedbush Research Analysts Lift Earnings Estimates for Aimmune Therapeutics Inc (AIMT)
www.americanbankingnews.com - March 19 at 2:14 AM |
 | AIMMUNE THERAPEUTICS, INC. - StreetInsider.com
www.streetinsider.com - March 13 at 8:41 AM |
| Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results - Business Wire (press release)
www.businesswire.com - March 13 at 8:41 AM |
| Aimmune Therapeutics Inc (AIMT) Short Interest Up 49.0% in February
www.americanbankingnews.com - March 13 at 1:53 AM |
| Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 12 at 11:01 AM |
| Zacks: Brokerages Expect Aimmune Therapeutics Inc (AIMT) Will Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - March 7 at 3:18 PM |
| Aimmune Therapeutics to Participate in Four Investor Conferences in March - Business Wire (press release)
www.businesswire.com - March 7 at 8:38 AM |
| Aimmune Therapeutics to Participate in Four Investor Conferences in March
finance.yahoo.com - March 7 at 8:38 AM |
| Cantor Fitzgerald Analysts Lower Earnings Estimates for Aimmune Therapeutics Inc (AIMT)
www.americanbankingnews.com - March 7 at 7:26 AM |
| Douglas T. Sheehy Sells 3,523 Shares of Aimmune Therapeutics Inc (AIMT) Stock
www.americanbankingnews.com - March 6 at 9:44 PM |
| Aimmune Therapeutics (AIMT) Receives "Outperform" Rating from Wedbush
www.americanbankingnews.com - March 6 at 2:17 PM |
| Your Daily Pharma Scoop: Aimmune Data, Onconova Shares Get A Boost, G1 Therapeutics' Positive Data - Seeking Alpha
seekingalpha.com - March 6 at 8:31 AM |
| Aimmune Therapeutics Inc (AIMT) Insider Mary M. Rozenman Sells 1,807 Shares
www.americanbankingnews.com - March 5 at 7:34 PM |
| Aimmune Therapeutics (AIMT) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - March 5 at 5:34 PM |
| Aimmune Therapeutics (AIMT) PT Set at $47.00 by Credit Suisse Group
www.americanbankingnews.com - March 5 at 4:30 PM |
| Roth Capital Raises Aimmune Therapeutics (AIMT) Price Target to $80.00
www.americanbankingnews.com - March 5 at 9:45 AM |
| Aimmune Therapeutics (AIMT) Reports Positive Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy - StreetInsider.com
www.streetinsider.com - March 5 at 8:35 AM |
| Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO
finance.yahoo.com - March 4 at 6:14 PM |
| Aimmune Therapeutics: Insider Buying Alert - Seeking Alpha
seekingalpha.com - March 4 at 8:33 AM |
| Aimmune Therapeutics (AIMT) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 4 at 12:16 AM |
| Aimmune Therapeutics Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
finance.yahoo.com - March 2 at 5:54 PM |
| Peanut Allergy-Focused Biotech May Strike Magic in Orlando
finance.yahoo.com - March 2 at 5:54 PM |
| Aimmune Therapeutics to Host Analyst and Investor Event Following ... - Business Wire (press release)
www.businesswire.com - March 1 at 8:27 AM |
| Aimmune Therapeutics (AIMT) Given New $62.00 Price Target at Royal Bank of Canada
www.americanbankingnews.com - February 27 at 3:32 PM |
| Aimmune Therapeutics (AIMT) Given a $62.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - February 27 at 3:31 PM |
 | Oversold Conditions For Aimmune Therapeutics (AIMT)
www.nasdaq.com - February 27 at 8:35 AM |
| Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results on Sunday, March 4, at the AAAAI-WAO Joint Congress in Orlando
finance.yahoo.com - February 27 at 8:35 AM |
| Insider Buying: Aimmune Therapeutics Inc (AIMT) CFO Acquires 3,125 Shares of Stock
www.americanbankingnews.com - February 26 at 9:22 PM |
| Aimmune Therapeutics Inc (AIMT) Director Purchases $498,976.00 in Stock
www.americanbankingnews.com - February 26 at 6:34 PM |
| Insider Buying: Aimmune Therapeutics Inc (AIMT) Major Shareholder Buys 9,375 Shares of Stock
www.americanbankingnews.com - February 26 at 6:34 PM |
| Insider Buying: Aimmune Therapeutics Inc (AIMT) Director Acquires 30,000 Shares of Stock
www.americanbankingnews.com - February 26 at 6:18 PM |
Aimmune Therapeutics (NASDAQ:AIMT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aimmune Therapeutics (NASDAQ:AIMT) Income Statement, Balance Sheet and Cash Flow Statement
Aimmune Therapeutics (NASDAQ AIMT) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
